- Home
- BXP vs SNN Comparison
BXP vs SNN Comparison
Compare BXP & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXP | SNN |
|---|---|---|
| Founded | 1970 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 12.3B |
| IPO Year | 2000 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BXP | SNN |
|---|---|---|
| Price | $67.87 | $28.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 2 |
| Target Price | ★ $71.94 | $36.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 04-28-2026 | 03-16-2026 |
| Dividend Yield | ★ 4.86% | 2.48% |
| EPS Growth | ★ 1833.33 | N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $3,482,279,000.00 | N/A |
| Revenue This Year | $11.00 | $8.58 |
| Revenue Next Year | $2.91 | $5.60 |
| P/E Ratio | ★ $63.81 | $64.97 |
| Revenue Growth | ★ 2.19 | N/A |
| 52 Week Low | $49.93 | $28.48 |
| 52 Week High | $79.33 | $38.79 |
Technical Indicators
Market Signals| Indicator | BXP | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 38.66 |
| Support Level | $68.17 | N/A |
| Resistance Level | $70.54 | $31.36 |
| Average True Range (ATR) | 1.60 | 0.47 |
| MACD | -0.19 | -0.07 |
| Stochastic Oscillator | 34.68 | 8.59 |
Price Performance
Historical ComparisonAbout BXP Boston Properties Inc.
BXP owns 179 properties consisting of approximately 52.6 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.